Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-01-22
2003-10-07
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S385000
Reexamination Certificate
active
06630508
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to novel cycloalkyl-benzopyrans and derivatives thereof, compositions containing those compounds, their use as selective estrogen receptor-beta agonists, and their use in the treatment of estrogen receptor-beta mediated diseases such as prostate cancer, benign prostatic hyperplasia, testicular cancer, ovarian cancer, lung cancer, cardiovascular diseases, neurodegenerative disorders, urinary incontinence, central nervous system (CNS) conditions, gastrointestinal (GI) tract conditions, and osteoporosis.
Estrogens play important roles in the development and homeostasis of the reproductive, central nervous, skeletal, and cardiovascular systems of both males and females. The estrogen receptor (ER) is currently the only member of the steroid subfamily of nuclear receptors that has different subtypes. Recently, a new ER isoform, ER-beta (also known as ER-betal) was cloned from a rat prostatic cDNA library and is present in murine and human prostates. Consequently, the previous ER is now designated as ER-alpha. ER-alpha and ER-beta share high amino acid homology, have similar 17-&bgr; Estradiol (E2) binding affinities, and can hetero- or homodimerize to form a signaling complex; Kuiper G G, et al., Endocrinol. 138: 863-70 (1997); Kuiper G G et al., Proc. Natl. Acad. Sci. USA 93: 5925-30 (1996). Although E2 activates both ER-alpha and ER-beta, ER-alpha stimulates transcription and cellular proliferation, while ER-beta suppresses ER-alpha activation. Interestingly, 3-beta, 17-beta-androstanediol and 5-alpha-androstane have been proposed to be endogenous ligands for ER-beta; Weihua Z. et al. PNAS 98:6330-5 (2001). 3-Beta, 17-beta-androstanediol is a major metabolite of dihydrotestosterone (DHT), the 5-alpha-reduced active intracellular androgen in male accessory sex organs. ER-beta activation also stimulates increased glutathione S-transferase and quinone reductase expression. These two enzymes have been shown to possess chemoprotective detoxification properties; Chang W Y et al., Prostate 40: 115-24 (1999); Montano M M et al., J. Biol. Chem. 273: 25443-9 (1998).
With the recent identification of ER-beta, and the recognition that ER-alpha and ER-beta have different biological roles, ER-selective modulators would similarly possess significant clinical utility. Since ER-beta is strongly expressed in a number of tissues including prostate, bladder, ovary, testis, lung, small intestine, vascular endothelium, and various parts of the brain, compounds that selectively modulate ER-beta would be of clinical importance in the treatment of a variety of disease conditions, such as prostate cancer, testicular cancer, ovarian cancer, lung cancer, cardiovascular diseases, neurodegenerative disorders, urinary incontinence, CNS disorders, GI tract conditions, and osteoporosis. Such compounds would have minimal effect on tissues that contain ER-alpha, and thus exhibit different side-effect profiles. Thus, ER-beta agonists will display different therapeutic profiles compared to ER-alpha antagonists or agonists, and would be preferentially beneficial in tissues relying on ER-beta signaling.
The prostate gland produces components that are found in the semen and blood. Some of these are regulatory peptides. The prostate gland comprises stroma and epithelium cells, the latter group consisting of columnar secretory cells and basal non-secretory cells. The proliferation of these basal cells, as well as stroma cells gives rise to benign prostatic hyperplasia (BPH), which is one common prostate disease. BPH is a progressive condition that is characterized by the nodular enlargement of the prostatic tissue resulting in obstruction of the urethra. This results in increased frequency of urination, noncuria, poor urine stream, and hesitation or delay in starting the urine flow. Consequences of BPH can include hypertrophy of bladder smooth muscle, decompensated bladder, and increased incidence of urinary tract infection. The development of BPH is considered to be an inescapable phenomenon for the aging male population. BPH is observed in approximately 70% of males over the age of 70. Drug treatment for BPH currently employs alpha andrenergic antagonists for symptomatic relief or steroid 5-alpha reductase inhibitors to reduce hyperplastic tissue bulk. These approaches are of limited therapeutic benefit.
Mortality due to prostatic cancer when the strategem of watchful waiting is adopted is generally low (9%-15%) in men who have localized tumors. However, these rates pertain to patients with localized disease; they do not necessarily apply to younger men at higher risk. Younger men with stage T1a tumors have a longer projected period of risk than older men with the same stage of the disease and are therefore candidates for a potentially curative treatment. In studies of watchful waiting, the high rates of disease progression (34%-80%) indicate that few clinically evident prostate cancers are dormant.
BRIEF SUMMARY OF THE INVENTION
The present invention relates to novel benzopyran derivatives of formula (I):
wherein
R
1
and R
2
are each independently —H, C
1
-C
6
alkyl, —OH, C
1
-C
6
alkoxy, halo, or —CF
3
;
R
3
is —H, C
1
-C
6
alkyl, halo, or —CF
3
;
Y
1
, Y
2
, and Y
3
are each independently —H or C
1
-C
6
alkyl; and G is —CH
2
—, —CH
2
—CH
2
—, or —CH
2
—CH
2
—CH
2
—;
with the proviso that when G is —CH
2
— and R
1
, R
2
, R
3
, Y
2
, and Y
3
are all —H, then Y
1
cannot be methyl;
or a pharmaceutically acceptable salt thereof.
Compounds of the invention are the following:
a) (±)-2-phenyl-6-hydroxy-cyclopentyl[c]3,4-dihydro-2H-1-benzopyran
b) (±)-2-(4-fluorophenyl)-6-hydroxy-cyclopentyl[c]3,4-dihydro-2H-1-benzopyran
c) (±)-2-(4-ethylphenyl)-6-hydroxy-cyclopentyl[c]3,4-dihydro-2H-1-benzopyran
d) (±)-2-(4-trifluoromethylphenyl)-6-hydroxy-cyclopentyl[c]3,4-dihydro-2H-1-benzopyran
e) (±)-2-(3-hydroxyphenyl)-6-hydroxy-cyclopentyl[c]3,4-dihydro-2H-1-benzopyran
f) (±)-2-(4-methylphenyl)-6-hydroxy-cyclopentyl[c]3,4-dihydro-2H-1-benzopyran
In a second embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier.
In a further embodiment, the present invention provides medical methods of employing compounds of formula (I) as agonists of estrogen receptor ER beta, further utilized for the treatment of estrogen receptor ER beta-mediated diseases such as prostate cancer, benign prostatic hyperplasia, testicular cancer, cardiovascular diseases, neurodegenerative disorders, urinary incontinence, central nervous system (CNS) conditions, gastrointestinal (GI) tract conditions, and osteoporosis.
DETAILED DESCRIPTION OF THE INVENTION
As used in this application:
a) the term “halogen” refers to a fluorine atom, chlorine atom, bromine atom, or iodine atom;
b) the term “C
1
-C
6
alkyl” refers to a branched or straight chained alkyl radical containing from 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec butyl, t-butyl, pentyl, hexyl, etc.;
c) the term “C
1
-C
6
alkoxy” refers to a straight or branched alkoxy group containing from 1 to 6 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy, pentoxy, hexoxy, etc;
d) the designation “
” refers to a bond for which the stereochemistry is not designated;
e) the designation “
” refers to a bond that protrudes forward out of the plane of the page;
f) the designation “
” refers to a bond that protrudes backward out of the plane of the page;
g) as used in the preparations and examples the following terms have the indicated meanings; “ng” refers to nanograms; “&mgr;g” refers to micrograms; “mg” refers to milligrams; “g” refers to grams; “kg” refers to kilograms; “nmole” refers to nanomoles; “mmol” refers to millimoles; “mol” refers to moles; “&mgr;L” refers to microliters; “mL” refers to milliliters; “L” refers to lite
Dodge Jeffrey Alan
Krishnan Venkatesh
Lugar, III Charles Willis
Neubauer Blake Lee
Aulakh Charanjit S.
Eli Lilly and Company
Sayles Michael J.
LandOfFree
Substituted benzopyrans as selective estrogen receptor &bgr;... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzopyrans as selective estrogen receptor &bgr;..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzopyrans as selective estrogen receptor &bgr;... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3157490